hPTH-(1-34) crystallizes as a slightly bent, long helical dimer. Analysis reveals that the extended helical conformation of hPTH-(1-34) is the likely bioactive conformation. The N-terminal fragment 1-34 of parathyroid hormone (PTH) has been crystallized and the structure has been refined to 0.9 Å resolution.
It enhances the release of calcium from the large reservoir contained in the bones.Bone resorption is the normal destruction of bone by osteoclasts, which are indirectly stimulated by PTH. Stimulation is indirect since osteoclasts do not have a receptor for PTH; rather, PTH binds to osteoblasts, the cells responsible for creating bone. Binding stimulates osteoblasts to increase their expression of RANKL and inhibits their expression of Osteoprotegerin (OPG). OPG binds to RANKL and blocks it from interacting with RANK, a receptor for RANKL. The binding of RANKL to RANK (facilitated by the decreased amount of OPG available for binding the excess RANKL) stimulates these osteoclast precursors to fuse, forming new osteoclasts, which ultimately enhances bone resorption.
It enhances active reabsorption of calcium and magnesium from distal tubules and the thick ascending limb. As bone is degraded, both calcium and phosphate are released. It also decreases the reabsorption of phosphate, with a net loss in plasma phosphate concentration. When the calcium:phosphate ratio increases, more calcium is free in the circulation.
However, PTH enhances the uptake of phosphate from the intestine and bones into the blood. In the bone, slightly more calcium than phosphate is released from the breakdown of bone. In the intestines, absorption of both calcium and phosphate is mediated by an increase in activated vitamin D. The absorption of phosphate is not as dependent on vitamin D as is that of calcium. The end result of PTH release is a small net drop in the serum concentration of phosphate.
Vitamin D synthesis
PTH increases the activity of 1-α-hydroxylase enzyme, which converts 25-hydroxycholecalciferol to 1,25-dihydroxycholecalciferol, the active form of vitamin D.
Interactive pathway map
Click on genes, proteins and metabolites below to link to respective articles.[§ 1]
Secretion of parathyroid hormone is controlled chiefly by serum [Ca2+] through negative feedback. Calcium-sensing receptors located on parathyroid cells are activated when [Ca2+] is elevated. The G-protein coupled calcium receptors bind extracellular calcium and may be found on the surface on a wide variety of cells distributed in the brain, heart, skin, stomach, C cells, and other tissues. In the parathyroid gland, high concentrations of extracellular calcium result in activation of the Gq G-protein coupled cascade through the action of phospholipase C. This hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) to liberate intracellular messengers IP3 and diacylglycerol (DAG). Ultimately, these two messengers result in a release of calcium from intracellular stores and a subsequent flux of extracellular calcium into the cytoplasmic space. The effect of this signaling of high extracellular calcium results in an intracellular calcium concentration that inhibits the secretion of preformed PTH from storage granules in the parathyroid gland. In contrast to the mechanism that most secretory cells use, calcium inhibits vesicle fusion and release of PTH.
In the parathyroids, magnesium serves this role in stimulus-secretion coupling. Hypomagnesemia inhibits PTH secretion and also causes resistance to PTH, leading to a form of hypoparathyroidism that is reversible. Hypermagnesemia also results in inhibition of PTH secretion.[further explanation needed]
Decreased serum [Ca2+].
Mild decreases in serum [Mg2+].
An increase in serum phosphate (increased phosphate causes it to complex with serum calcium, forming calcium phosphate, which reduces stimulation of Ca-sensitive receptors (CaSr) that do not sense calcium phosphate, triggering an increase in PTH).
Hyperparathyroidism, the presence of excessive amounts of parathyroid hormone in the blood, occurs in two very distinct sets of circumstances. Primary hyperparathyroidism is due to autonomous, abnormal hypersecretion of PTH from the parathyroid gland, while secondary hyperparathyroidism is an appropriately high PTH level seen as a physiological response to hypocalcaemia.
A low level of PTH in the blood is known as hypoparathyroidism and is most commonly due to damage to or removal of parathyroid glands during thyroid surgery.
In osteoporotic women, administration of an exogenous parathyroid hormone analogue (teriparatide, by daily injection) superimposed on estrogen therapy produced increases in bone mass and reduced vertebral and nonvertebral fractures by 45 to 65%.
PTH can be measured in the blood in several different forms: intact PTH; N-terminal PTH; mid-molecule PTH, and C-terminal PTH, and different tests are used in different clinical situations.
^Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (May 2001). "Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis". N. Engl. J. Med.344 (19): 1434–41. doi:10.1056/NEJM200105103441904. PMID11346808.
^Longo et al. Harrison's Principles of Internal Medicine, 18th ed., p.3594
Drüeke TB, Massy ZA (2003). "Advanced oxidation protein products, parathyroid hormone and vascular calcification in uremia". Blood Purif.20 (5): 494–7. doi:10.1159/000065203. PMID12207101.
Keutmann HT, Sauer MM, Hendy GN, et al. (1979). "Complete amino acid sequence of human parathyroid hormone". Biochemistry17 (26): 5723–9. doi:10.1021/bi00619a019. PMID728431.
Keutmann HT, Niall HD, O'Riordan JL, Potts JT (1975). "A reinvestigation of the amino-terminal sequence of human parathyroid hormone". Biochemistry14 (9): 1842–7. doi:10.1021/bi00680a006. PMID1125201.
Parkinson DB, Thakker RV (1993). "A donor splice site mutation in the parathyroid hormone gene is associated with autosomal recessive hypoparathyroidism". Nat. Genet.1 (2): 149–52. doi:10.1038/ng0592-149. PMID1302009.
Handt O, Reis A, Schmidtke J (1993). "Ectopic transcription of the parathyroid hormone gene in lymphocytes, lymphoblastoid cells and tumour tissue". J. Endocrinol.135 (2): 249–56. doi:10.1677/joe.0.1350249. PMID1474331.
Tonoki H, Narahara K, Matsumoto T, Niikawa N (1991). "Regional mapping of the parathyroid hormone gene (PTH) by cytogenetic and molecular studies". Cytogenet. Cell Genet.56 (2): 103–4. doi:10.1159/000133059. PMID1672845.
Marx UC, Adermann K, Bayer P, et al. (1998). "Structure-activity relation of NH2-terminal human parathyroid hormone fragments.". J Biol Chem.273 (8): 4308–16. doi:10.1074/jbc.273.8.4308. PMID9468478.
Nussbaum SR, Gaz RD, Arnold A (1990). "Hypercalcemia and ectopic secretion of parathyroid hormone by an ovarian carcinoma with rearrangement of the gene for parathyroid hormone". N. Engl. J. Med.323 (19): 1324–8. doi:10.1056/NEJM199011083231907. PMID2215618.
Ahn TG, Antonarakis SE, Kronenberg HM, et al. (1986). "Familial isolated hypoparathyroidism: a molecular genetic analysis of 8 families with 23 affected persons". Medicine (Baltimore)65 (2): 73–81. doi:10.1097/00005792-198603000-00001. PMID3005800.
Tregear GW, van Rietschoten J, Greene E, et al. (1975). "Solid-phase synthesis of the biologically active N-terminal 1 - 34 peptide of human parathyroid hormone". Hoppe-Seyler's Z. Physiol. Chem.355 (4): 415–21. PMID4474131.
Hendy GN, Bennett HP, Gibbs BF, et al. (1995). "Proparathyroid hormone is preferentially cleaved to parathyroid hormone by the prohormone convertase furin. A mass spectrometric study". J. Biol. Chem.270 (16): 9517–25. doi:10.1074/jbc.270.16.9517. PMID7721880.